Diabetes is a disease that occurs when your blood glucose, also called blood sugar, is too high. Blood glucose is your main source of energy and comes from the food you eat. Insulin, a hormone made by the pancreas, helps glucose from food get into your cells to be used for energy. Sometimes your body doesn’t make enough insulin or doesn’t use insulin well. Glucose then stays in your blood and doesn’t reach your cells. Over time, having too much glucose in your blood can cause health problems.
What are the different types of diabetes?
The most common types of diabetes are type 1 and type 2
Type 1 diabetes
If you have type 1 diabetes, your body does not make insulin. Your immune system attacks and destroys the cells in your pancreas that make insulin. Type 1 diabetes is usually diagnosed in children and young adults, although it can appear at any age. People with type 1 diabetes need to take insulin every day to stay alive.
Type 2 diabetes
If you have type 2 diabetes, your body resist the action of insulin. You can develop type 2 diabetes at any age, even during childhood. However, this type of diabetes occurs most often in middle-aged and older people. Type 2 is the most common type of diabetes.
My HealthWorks has formulations which can help correct this.
Though high level of sugar than normal is always associated with both Type 1 and Type 2 diabetes, there are certain differentiators between the two as mentioned below.
Though the perfect cause that leads to type 1 diabetes is unknown, some aspects that lead to this disease are:
Individuals are affected by type 2 diabetes when their pancreas stops producing adequate insulin for maintaining normal level of blood glucose, or if their body is not able to utilize produced insulin. Some important factors that lead to type 2 diabetes include:
Signs and symptoms that suggest presence of this disease are:
are usually diagnosed during check-ups. The reason for this is that these signs are mostly mild and gradually develop over years. Some signs associated with this disease are:
Some complications associated with this ailment are:
The following tests are suggested for diagnosis of type 1 diabetes:
Following are certain things you can follow in both Type 1 and Type 2 Diabetes to keep this ailment at bay:
Treatment methods for this disease include:
The following My HealthWorks Packages recommended for treatment.
| SNO. | REVERSAL | RECOVERY | RESTORATION & MAINTAINANCE | ||||||
| 1 | DIABETES | ||||||||
| GYMNEMA SUGARKEY | PRIMROSE OMEGA-369 | PROTOMAX | |||||||
| DIABCOL | NANO CURCUMIN | COCONUT MIRACLE-X | |||||||
| MULTIMAX | |||||||||
| ALOE VERA | |||||||||
When a diabetic follows the regimen of My HealthWorks he\she gradually reports improvement in symptoms, sometimes amazingly within a week only. Then we monitor Blood parameters to record and demonstrate gradual recovery. Then under a doctor's guidance gradually Insulin \ Oral medications are reduced and discontinued based on both clinical and laboratory parameters and recovery levels.
Finally the person continues some supplements and nutrients for Balanced Wellness.
This way we take the Diabetic from disorder to Recovery thru Cellular Nutrition, Reversal of Lifestyle Disorder and Restoration of Health and Wellness.
Short-term effect of G-400, polyherbal formulation in the management of hyperglycemiaand hyperlipidemiaconditions in patients with type 2 diabetes mellitus. Kurian GA1, Manjusha V2, Nair SS2, Varghese T2, Padikkala J3. Author information Abstract OBJECTIVE: Salacia oblonga, Tinospora cordifolia, Emblica offinalis Gaertn, Curcuma longa and Gymnema sylvestre are Ayurvedic medicinal plants reported to lower plasma glucose levels in animal models. To our knowledge, however, no clinical validations of those extracts for efficacy have been. The aim of this study was to evaluate the effect of polyherbal combination in patients with type 2 diabetes mellitus. METHODS: We screened 250 patients enrolled in a diabetes mellitus screening camp held at District Ayurvedic Hospital, Kottayam, Kerala, India. Of these, 89 patients diagnosed with type 2 diabetes mellitus and 50 healthy volunteers of similar age group were included in the study. Patients were treated with a polyherbal combination drug namely G400 (1000 mg/d) for 8 wk with a follow-up of 2wk interval. RESULTS: Fasting and postprandial blood glucose levels measured after 8 wk of G-400 treatment in patients were significantly lower. Indeed diabetic rats showed similar protection with G-400 administration. Furthermore, glycosylated hemoglobin, serum total cholesterol, both high- and low-density lipoprotein cholesterol, and triglycerides showed a significant improvement in G-400-administered patients. Toxicologic profile of the drug was assessed by analyzing the enzyme activities of alkaline phosphatase and alanine aminotransferase along with the concentration of blood urea nitrogen and creatinine in blood and found insignificant change compared with control. CONCLUSION: Short-term supplementation of G-400 not only attenuates the hyperglycemia, but also acts as hypolipidemic agent in patients with diabetes. Further study should be done for the long-term effect of the drug in larger populations.
An open label study on the supplementation of Gymnema sylvestre in type 2 diabetics. Kumar SN1, Mani UV, Mani I. Author information Abstract Diabetes mellitus is a complex metabolic disorder characterized by chronic hyperglycemia, and associated with long-term damage and dysfunction of various organs. Management of diabetes is therefore vital and involves maintaining euglycemia as much as possible by reducing blood glucose and by increasing insulin sensitivity and peripheral glucose uptake. Ayurveda has promoted the management of diabetes by regulating carbohydrate metabolism using several medicinal herbs, one of which is Gymnema sylvestre (GS). GS has been used in parts of India as a hypoglycemic agent and the results have been encouraging. Accordingly, we planned a quasi-experimental study to investigate the efficacy of the herb among type 2 diabetics. Patients enrolled from free-living population were purposively assigned to experimental or control groups, based on their willingness to participate in the study. The experimental group was supplemented with 500 mg of the herb per day for a period of 3 months, and the efficacy of the herb was assessed through a battery of clinical and biochemical tests. Supplementation of the diet with GS reduced polyphagia, fatigue, blood glucose (fasting and post-prandial), and glycated hemoglobin and there was a favorable shift in lipid profiles and in other clinico-biochemical tests. These findings suggest a beneficial effect of GS in the management of diabetes mellitus.
A systematic review of Gymnema sylvestre in obesity and diabetes management. Pothuraju R1, Sharma RK, Chagalamarri J, Jangra S, Kumar Kavadi P. Author information Abstract The prevalence of obesity is associated with many health-related problems. Currently, more than 300 million people are considered to be obese. According to the World Health Organization (WHO), by 2030, 87 and 439 million people will be affected in India and the world, respectively. Today, herbal medicines are gaining interest in the treatment of obesity and diabetes, because of their minimal side effects. Gymnemic acid - an active component isolated from Gymnema sylvestre - has anti-obesity and antidiabetic properties, decreases body weight and also inhibits glucose absorption. Several components extracted from Gymnema prevent the accumulation of triglycerides in muscle and liver, and also decrease fatty acid accumulation in the circulation. In this paper, an attempt has been made to review the effects of various extracts from Gymnema sylvestre in the regulation of carbohydrate and lipid metabolism in both animal and clinical studies.
Soy Protein Supplementation Reduces Clinical Indices in Type 2 Diabetes and Metabolic Syndrome. Zhang XM1, Zhang YB2, Chi MH3. Author information Abstract PURPOSE: Clinical trials have studied the use of soy protein for treating type 2 diabetes (T2D) and metabolic syndrome (MS). The purpose of this study was to outline evidence on the effects of soy protein supplementation on clinical indices in T2D and MS subjects by performing a meta-analysis of randomized controlled trials (RCTs). MATERIALS AND METHODS: We searched PubMed, EMBASE, and Cochrane databases up to March 2015 for RCTs. Pooled estimates and 95% confidence intervals (CIs) were calculated by the fixed-and-random-effects model. A total of eleven studies with eleven clinical variables met the inclusion criteria. RESULTS: The meta-analysis showed that fasting plasma glucose (FPG) [weighted mean difference (WMD), -0.207; 95% CI, -0.374 to -0.040; p=0.015], fasting serum insulin (FSI) (WMD, -0.292; 95% CI, -0.496 to -0.088; p=0.005), homeostasis model of assessment for insulin resistance index (HOMA-IR) (WMD, -0.346; 95% CI, -0.570 to -0.123; p=0.002), diastolic blood pressure (DBP) (WMD, -0.230; 95% CI, -0.441 to -0.019; p=0.033), low-density lipoprotein cholesterol (LDL-C) (WMD, 0.304; 95% CI, -0.461 to -0.148; p=0.000), total cholesterol (TC) (WMD, -0.386; 95% CI, -0.548 to -0.225; p=0.000), and Creactive protein (CRP) (WMD, -0.510; 95% CI, -0.722 to -0.299; p=0.000) are significant reduced with soy protein supplementation, compared with a placebo control group, in T2D and MS patients. Furthermore, soy protein supplementation for longer duration (6 mo) significantly reduced FPG, LDL-C, and CRP, while that for a shorter duration (6 mo) significantly reduced FSI and HOMA-IR. CONCLUSION: Soy protein supplementation could be beneficial for FPG, FSI, HOMA-IR, DBP, LDL-C, TC, and CRP control in plasma.
Insulin sensitising action of chromium picolinate in various experimental models of diabetes mellitus. Shindea UA1, Sharma G, Xu YJ, Dhalla NS, Goyal RK. Author information Abstract Although chromium is an essential element for carbohydrate and lipid metabolism, its effects in diabetic patients are still debated. We have studied the effect of 6 week treatment with chromium picolinate (8 microg/ml in drinking water) in streptozotocin (STZ)-induced type 1 and type 2 diabetic rat models. The mechanism of anti-diabetic action of chromium picolinate was studied using C2C12 myoblasts and 3T3-L1 adipocytes. Chromium picolinate significantly decreased the area under the curve over 120 min for glucose of both STZ-induced type 1 (40mg/kg, i.v. in adult rats) and type 2 (90 mg/kg, i.p. in 2 day old rat neonates) diabetic rats without any significant change in area under the curve over 120 min for insulin as compared to controls. The composite insulin sensitivity index and insulin sensitivity index (KITT) values of both type 1 and type 2 diabetic rats were increased significantly by chromium picolinate. Treatment with chromium picolinate produced a significant decrease in elevated cholesterol and triglyceride levels in both types of diabetic rats. In 3T3-L1 adipocytes, chromium picolinate (0-10 micromol) per se did not produce any effect, however, when co-incubated with insulin it significantly increased the intracellular triglyceride synthesis (EC50 = 363.7nmol/1). Similarly in C2C12 myoblasts, chromium picolinate alone did not produce any effect, however, it significantly increased insulin-induced transport of 14C-glucose. In conclusion, chromium picolinate significantly improves deranged carbohydrate and lipid metabolism of experimental chemically induced diabetes in rats. The mechanism of in vivo anti-diabetic action appears to be peripheral (skeletal muscle and adipose tissue) insulin enhancing action of chromium.
My name is Mike, and I'm the head coach here at HealthAshtam.
I'll be also your coach! Let's get to
know each other - what is your name?
My name is Mike, and I'm the head coach here at HealthAshtam.
I'll be also your coach! Let's get to
know each other - what is your name?
